

the 1990s, the incidence of *S. flexneri* has increased in the United Kingdom [10]. In the United States, *S. flexneri* has been reported as the most common serotype in children with acute bacterial dysentery [11]. In the United Kingdom, *S. flexneri* has been reported as the most common serotype in children with acute bacterial dysentery [12].

There is a need to develop a vaccine against *S. flexneri* to protect children in developing countries. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.

The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.

The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.

The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.

The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.

The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.

The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.

The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease. The development of a vaccine against *S. flexneri* is hampered by the lack of a suitable animal model for the disease.